LifeSteps Financial Inc. Boosts Stake in Genelux Co. (NASDAQ:GNLX)

LifeSteps Financial Inc. increased its stake in Genelux Co. (NASDAQ:GNLX) by 11.1% during the fourth quarter, Holdings Channel.com reports. The institutional investor owned 86,970 shares of the company’s stock after buying an additional 8,715 shares during the period. LifeSteps Financial Inc.’s holdings in Genelux were worth $205,000 as of its most recent filing with the SEC.

Several other large investors also recently modified their holdings of GNLX. Geode Capital Management LLC raised its holdings in Genelux by 39.7% during the 3rd quarter. Geode Capital Management LLC now owns 316,160 shares of the company’s stock valued at $749,000 after acquiring an additional 89,854 shares during the period. XTX Topco Ltd purchased a new position in Genelux during the third quarter worth about $59,000. D.A. Davidson & CO. bought a new position in Genelux in the 4th quarter worth about $51,000. Brown Brothers Harriman & Co. increased its position in shares of Genelux by 76.2% in the third quarter. Brown Brothers Harriman & Co. now owns 21,075 shares of the company’s stock worth $50,000 after purchasing an additional 9,114 shares during the last quarter. Finally, Apollon Wealth Management LLC raised its position in shares of Genelux by 20.4% during the 4th quarter. Apollon Wealth Management LLC now owns 16,863 shares of the company’s stock valued at $40,000 after buying an additional 2,857 shares in the last quarter. Hedge funds and other institutional investors own 37.33% of the company’s stock.

Genelux Trading Up 0.4 %

Genelux stock opened at $4.84 on Friday. The company has a market capitalization of $167.17 million, a price-to-earnings ratio of -5.09 and a beta of -1.46. Genelux Co. has a 12 month low of $1.60 and a 12 month high of $8.67. The business’s fifty day simple moving average is $3.36 and its two-hundred day simple moving average is $2.81.

Analyst Ratings Changes

GNLX has been the topic of a number of recent research reports. HC Wainwright reduced their price target on shares of Genelux from $32.00 to $30.00 and set a “buy” rating on the stock in a research report on Friday, November 15th. Guggenheim started coverage on Genelux in a report on Tuesday, October 29th. They set a “buy” rating and a $8.00 target price for the company. Four research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Buy” and an average price target of $18.25.

Genelux Profile

Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec, a proprietary modified strain of the vaccinia virus for the treatment of ovarian cancer and non-small cell lung cancer.